Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-8068 + Adebrelimab + Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
NCT07682272Phase 2Not yet recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CS1002 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoint: Major Pathological Response Rate at 3 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
CS1002
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07682272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07682272.